[{"orgOrder":0,"company":"Fathom Pharma","sponsor":"Consegna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"FP01","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Fathom Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fathom Pharma \/ Consegna Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fathom Pharma \/ Consegna Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Fathom Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Fathom joining Consegna, will accelerate the clinical development of combined LAI (long-acting injectables) focused on several aspects of pain signaling pathways. Fathom Pharma develops new treatments for chronic pain that includes FP01, as a treatment ...

                          Brand Name : FP01

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 19, 2022

                          Lead Product(s) : FP01

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Consegna Pharma

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank